JP2024525954A5 - - Google Patents
Info
- Publication number
- JP2024525954A5 JP2024525954A5 JP2024504002A JP2024504002A JP2024525954A5 JP 2024525954 A5 JP2024525954 A5 JP 2024525954A5 JP 2024504002 A JP2024504002 A JP 2024504002A JP 2024504002 A JP2024504002 A JP 2024504002A JP 2024525954 A5 JP2024525954 A5 JP 2024525954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- weight
- approximately
- compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163223711P | 2021-07-20 | 2021-07-20 | |
| US63/223,711 | 2021-07-20 | ||
| PCT/IB2022/056709 WO2023002407A2 (en) | 2021-07-20 | 2022-07-20 | Soluble pharmaceutical compositions comprising salts of disubstituted 1, 2, 4-triazine compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525954A JP2024525954A (ja) | 2024-07-12 |
| JP2024525954A5 true JP2024525954A5 (cg-RX-API-DMAC7.html) | 2025-07-24 |
Family
ID=84978780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504002A Pending JP2024525954A (ja) | 2021-07-20 | 2022-07-20 | 二置換1,2,4-トリアジン化合物の塩を含む可溶性薬学的組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240366616A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4373812A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525954A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240052937A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117957213A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023002407A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230069126A (ko) * | 2020-09-15 | 2023-05-18 | 미쓰비시 타나베 파마 코퍼레이션 | 트리아진 화합물의 염, 그 결정형 및 제조 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2193007T3 (es) * | 2000-02-17 | 2004-11-01 | Teva Pharmaceutical Industries Ltd. | Formulacion farmaceutica estable que comprende la modificacion ii de la torsemida. |
| SE0203778D0 (sv) * | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | A new oral immediated release dosage form |
| US20120059011A1 (en) * | 2009-06-15 | 2012-03-08 | Nicholas Birringer | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| GB201212866D0 (en) * | 2012-07-20 | 2012-09-05 | Formac Pharmaceuticals Nv | Dry granulates of mesoporous silica powders |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| CN114641278A (zh) * | 2019-09-11 | 2022-06-17 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶抑制剂的药物配制品 |
| KR20230069126A (ko) * | 2020-09-15 | 2023-05-18 | 미쓰비시 타나베 파마 코퍼레이션 | 트리아진 화합물의 염, 그 결정형 및 제조 방법 |
| US20240009201A1 (en) * | 2020-10-26 | 2024-01-11 | Mineralys Therapeutics, Inc. | Cyp11b2 beta hydroxylase inhibitors for hypertension |
-
2022
- 2022-07-20 KR KR1020247005631A patent/KR20240052937A/ko active Pending
- 2022-07-20 WO PCT/IB2022/056709 patent/WO2023002407A2/en not_active Ceased
- 2022-07-20 EP EP22845541.6A patent/EP4373812A4/en active Pending
- 2022-07-20 US US18/580,999 patent/US20240366616A1/en active Pending
- 2022-07-20 JP JP2024504002A patent/JP2024525954A/ja active Pending
- 2022-07-20 CN CN202280051082.5A patent/CN117957213A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512117A5 (cg-RX-API-DMAC7.html) | ||
| JP7860163B2 (ja) | Ag10の製剤 | |
| JP2021512081A (ja) | エソメプラゾール及び炭酸水素ナトリウムを含む安定な薬剤学的組成物 | |
| TWI895494B (zh) | 為錠劑形式之含奧美拉唑、埃索美拉唑或其醫藥上可接受鹽之醫藥組成物及其製備程序 | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むpH依存性薬物放出特性が改善した剤形 | |
| JP2023536667A5 (cg-RX-API-DMAC7.html) | ||
| TWI784575B (zh) | 一種複合物的藥物組合物及其製備方法 | |
| KR20100063088A (ko) | 서방성 아지스로마이신 고형 약형 | |
| AU2021390901A9 (en) | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid | |
| JP7585043B2 (ja) | レナリドミドを含む医薬組成物 | |
| KR102579095B1 (ko) | 에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 제형 | |
| JP2020147529A (ja) | ダビガトランエテキシラートを含む製剤および安定化方法 | |
| WO2019212426A2 (en) | Delayed release dexketoprofen composition | |
| KR101524264B1 (ko) | 발사르탄 함유 경구용 약학 조성물 | |
| JP2024500545A5 (cg-RX-API-DMAC7.html) | ||
| CZ2011872A3 (cs) | Farmaceutická formulace prasugrelu hydrobromidu | |
| JP7423297B2 (ja) | 口腔内崩壊錠およびその製造方法 | |
| KR101809886B1 (ko) | 소형화된 클래리트로마이신 경구투여 제제 | |
| CN101217943B (zh) | 药物活性组分的缓释剂型 | |
| EP2527006B1 (en) | Quetiapine Formulation Having a Controlled-Release Coating | |
| EP3677254B1 (en) | Solid oral pharmaceutical compositions of desvenlafaxine | |
| JP2021518424A (ja) | 様々な用量のレナリドミドの経口用錠剤組成物 | |
| WO2012050539A1 (en) | Pharmaceutical composition comprising eplerenone | |
| JP6684915B2 (ja) | 引湿性が改善されたカルベジロール速放性製剤{Carvedilol immediate release formulation having improved madescent} | |
| EP3545951B1 (en) | Oral tablet composition comprising dexlansoprazole, oral tablet comprising same and method for manufacturing same |